BioVie Inc. Announces Closing of $12 Million Public Offering

BioVie Inc. (NASDAQ: BIVI, BIVIW), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the closing of its previously announced underwritten public offering of 6,000,000 units, with each unit consisting of one share of common stock and one warrant (the “Warrants”) (or pre-funded units in lieu thereof, with each pre-funded unit consisting of one pre-funded warrant (“Pre-Funded Warrants”) and one Warrant). Each unit was sold to the public at a price of $2.00 per unit (and each pre-funded unit was sold to the public at the public offering price of each unit less the $0.0001 per share nominal exercise price for each Pre-Funded Warrant). In addition, the underwriter exercised in part its option to purchase up to an additional 667,300 Warrants pursuant to the over-allotment option granted to the underwriter in connection with the offering. The gross proceeds to the Company from the offering were approximately $12 million, before deducting underwriting discounts and commissions and other offering expenses. The Warrants included in the units and pre-funded units were approved for listing on the Nasdaq Capital Market and commenced trading under the symbol “BIVIW” on August 8, 2025. Each Warrant is immediately exercisable, entitles the holder to purchase one share of common stock at an exercise price of $2.50 per share and expires five years from the date of issuance. Each Pre-Funded Warrant is immediately exercisable, entitles the holder to purchase one share of common stock and may be exercised at any time until exercised in full.